Profil
David B.
Bowman served as President & CEO of NeuRxus, Inc. from 2004 to 2006.
Prior to that, he was Vice President of Operations at Repros Therapeutics, Inc. from 2002 to 2004.
He also held the position of Vice President of Product Development at APP Pharmaceuticals, Inc. Additionally, Bowman served as Vice President of Product Development at Fresenius Kabi Pharmaceuticals Holding LLC from 2006 to 2013.
Bowman received his undergraduate and graduate degrees from the University of Michigan.
Anciens postes connus de David B. Bowman
| Sociétés | Poste | Fin |
|---|---|---|
Fresenius Kabi Pharmaceuticals Holding LLC
 Fresenius Kabi Pharmaceuticals Holding LLC Pharmaceuticals: MajorHealth Technology Fresenius Kabi Pharmaceuticals Holding LLC is a pharmaceutical company, which engages in the development, manufacturing, and marketing of injectable pharmaceutical products. It primarily focuses on the injectable oncology, anti-infective, anesthetic/analgesic, and critical care markets. The firm manufactures products in each of the three basic forms, which include liquid, powder, and lyophilized or freeze-dried. Its products are generally used in hospitals, long-term care facilities, alternate care sites and clinics. The company was founded on July 2, 2008 and is headquartered in Wilmington, DE. | Corporate Officer/Principal | 01/01/2013 |
| NeuRxus, Inc. | President | 01/12/2006 |
| REPROS THERAPEUTICS INC | Directeur des opérations | 01/06/2004 |
APP Pharmaceuticals, Inc.
 APP Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology APP Pharmaceuticals, Inc. develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. It offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. The company is headquartered in Los Angeles, CA. | Corporate Officer/Principal | - |
Formation de David B. Bowman
| University of Michigan | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Repros Therapeutics, Inc.
 Repros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Repros Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the development of drugs to treat hormonal and reproductive systems disorders. Its products include Enclomiphene and Proellex. The company was founded on August 20, 1987 and is headquartered in The Woodlands, TX. | Health Technology |
APP Pharmaceuticals, Inc.
APP Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology APP Pharmaceuticals, Inc. develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. It offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. The company is headquartered in Los Angeles, CA. | Health Technology |
Fresenius Kabi Pharmaceuticals Holding LLC
Fresenius Kabi Pharmaceuticals Holding LLC Pharmaceuticals: MajorHealth Technology Fresenius Kabi Pharmaceuticals Holding LLC is a pharmaceutical company, which engages in the development, manufacturing, and marketing of injectable pharmaceutical products. It primarily focuses on the injectable oncology, anti-infective, anesthetic/analgesic, and critical care markets. The firm manufactures products in each of the three basic forms, which include liquid, powder, and lyophilized or freeze-dried. Its products are generally used in hospitals, long-term care facilities, alternate care sites and clinics. The company was founded on July 2, 2008 and is headquartered in Wilmington, DE. | Health Technology |
| NeuRxus, Inc. |
